Bank of America projects the S&P 500 will reach 7,800 in the next 12 months, implying a modest 2% gain from current levels despite inflation and interest rate worries. The bank also raised its year-end 2026 target to 7,400, noting the market is overdue for a correction after limited pullbacks this year. Risks include persistent inflation, Fed policy uncertainty, and tightening credit, with valuations assuming lower inflation than expected. Despite near-term volatility, Bank of America remains positive long-term, forecasting strong earnings growth driven by AI and automation.
Bank of America's new S&P 500 outlook is shared here with related market data for context. For readers following Financials-sector stocks on Pluang, 23 of 74 priced US Financials stocks rose while 50 fell. Notable prices include GS at USD 999.02 with a -2.93% change, C at USD 134.78 with a -2.91% change, and DB at USD 39.32 with a -2.87% change, as of Sep 14, 2026 22:25 WIB.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
